About this Journal Submit a Manuscript Table of Contents

The State of the Art of Biomarkers in Parkinsonian Syndromes

Call for Papers

The identification of reliable biomarkers for Parkinson’s disease (PD) may change our understanding of the disease pathogenesis and ignite the validation of new treatments. Hundreds of contributions have analyzed biochemical stigma in plasma and cerebrospinal fluid (CSF); for instance, the CSF profile utilized for AD diagnosis was translated in extrapyramidal disorders for identifying patients likely to develop dementia; the determination of α-synuclein levels revealed prognostic and diagnostic potential in PD early stage. Early preclinical molecular markers and risk factor also emerged in both familial and sporadic forms of PD.

The overall scenario is fascinating but confusing. Emphasis is hampered by different considerations: clinical motor signs may not correlate with acclaimed biomarkers. Second, PD is a multisystem syndrome, in which the nonmotor spectrum of impairment, the involvement of extra-CNS functions, and the progression rate vary profoundly from patient to patient or even differ dramatically in disease’s phenotypes. Hence, an enthusiastic use of biomarkers in nonlongitudinal studies might be speculative.

We invite investigators to provide original articles and reviews; we encourage papers examining strengths and limitations of the presently available CSF and plasma markers. The special issue might be subdivided into different sections, one devoted to pathogenesis (metabolomic-proteomic findings, microRNAs expression) and one focused on diagnosis (i.e., traditional biomakers of dementia-at-risk patients inside the LBD galaxy).

Papers dedicated solely to imaging biomarkers are out of focus, unless correlated (i.e., putaminal dopamine loss, structural changes, and sympathetic cardiac denervation) with biochemical/molecular biomarkers. Potential topics include, but are not limited to:

  • Catecholamine and their metabolite in CSF and plasma: Stage disease markers
  • Alpha-synuclein expression in human disease ad disease models
  • GCase gene mutations as risk factors for PD development
  • Preclinical molecular risk factors in PD and peripheral markers: Focus on familiar forms
  • Biomarkers for cognitive impairment in extrapyramidal disorders
  • New determination of cytokines
  • Vitamin D in PD and senescence: A component of frailty
  • MicroRNAs (miRNAs) as a new tool exploring alpha-synuclein-mediated pathogenesis and identifying disease and treatment-related therapeutic targets
  • Longitudinal validity of biomarkers in PD: Chances to predict disease progression rate or feature specific phenotypes

Before submission authors should carefully read over the journal's Authors Guidelines, which are located at http://www.hindawi.com/journals/bmri/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/submit/journals/bmri/neurology/tsab/ according to the following timetable:

Manuscript DueFriday, 27 June 2014
First Round of ReviewsFriday, 19 September 2014
Publication DateFriday, 14 November 2014

Lead Guest Editor

Guest Editors